Archives of Pharmacy Practice, 2016 Warfarin is recognized as the standard antithrombotic agent for stroke prevention. However, new oral anticoagulant such as dabigatran constitutes huge improvement to compensate for the limitation of warfarin.
Amal K Sulieman
doaj +1 more source
Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
Trauma Case Reports, 2021 Dabigatran is an oral anticoagulant directly acting as thrombin inhibitor. The monoclonal antibody idarucizumab was developed to reverse its anticoagulatory effects after application of a standardized dose.
Mathias Ströhle +4 more
doaj +1 more source
Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]
, 2018 © The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast +66 more
core +2 more sources
Dabigatran Monitoring Was Influenced by Thrombin Time Reagent With Different Thrombin Concentrations
Clinical and Applied Thrombosis/Hemostasis, 2019 To describe the effect of dabigatran on thrombin time (TT) reagents at different concentrations of thrombin. Pooled normal plasma enriched with dabigatran was dissolved in dimethylsulfoxide (DMSO) at concentrations of 0, 20, 50, 100, 200, 300, and 500 ng/
Xiaoping Xu, Qian Liang
doaj +1 more source
Hemopericardium and Cardiac Tamponade Associated with Dabigatran Use [PDF]
, 2012 OBJECTIVE: To describe 2 cases of hemopericardium following treatment with dabigatran. CASE SUMMARIES: A 70-year-old male with a history of dabigatran use presented with cough, fatigue, and bloody stools.
Dy, Eliza A., Shiltz, Dane L.
core +2 more sources
Primary care management for optimized antithrombotic treatment [PICANT]: study protocol for a cluster-randomized controlled trial [PDF]
, 2012 Background: Antithrombotic treatment is a continuous therapy that is often performed in general practice and requires careful safety management. The aim of this study is to investigate whether a best practice model that applies major elements of case ...
A Siebenhofer +45 more
core +2 more sources
Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. [PDF]
, 2020 OBJECTIVE: The evolution of non-vitamin K antagonist anticoagulants (NOACs) has changed the horizon of stroke prevention in atrial fibrillation (SPAF).
Acar, RD +12 more
core +1 more source
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. [PDF]
, 2015 Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like stroke.
Acharya, Tushar, Deedwania, Prakash
core +1 more source
Clinical and Applied Thrombosis/Hemostasis, 2020 The prothrombotic state in patients with atrial fibrillation (AF) is related to endothelial injury, the activation of platelets and the coagulation cascade.
Aleksandra Lenart-Migdalska MD +5 more
doaj +1 more source
Frontiers in Medicine, 2020 Background: Idarucizumab has been included in guidelines for the management of bleeding or surgical procedure in dabigatran-treated patients without need for biological monitoring.
Nicolas Gendron +39 more
doaj +1 more source